These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19127117)

  • 1. Potentiation of oncolytic virotherapy with armed shRNA.
    Guo W; Fang B
    Cancer Biol Ther; 2009 Jan; 8(1):92-3. PubMed ID: 19127117
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene.
    Zheng JN; Pei DS; Sun FH; Zhang BF; Liu XY; Gu JF; Liu YH; Hu XL; Mao LJ; Wen RM; Liu JJ; Li W
    Cancer Biol Ther; 2009 Jan; 8(1):84-91. PubMed ID: 19029834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activities of an oncolytic adenovirus equipped with a double siRNA targeting Ki67 and hTERT in renal cancer cells.
    Fang L; Cheng Q; Li W; Liu J; Li L; Xu K; Zheng J
    Virus Res; 2014 Mar; 181():61-71. PubMed ID: 24463503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Time Fluorescence Image-Guided Oncolytic Virotherapy for Precise Cancer Treatment.
    Yano S; Tazawa H; Kishimoto H; Kagawa S; Fujiwara T; Hoffman RM
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].
    Fujiwara T; Tanaka N
    Nihon Rinsho; 2007 Oct; 65(10):1913-22. PubMed ID: 17926546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The end of the beginning: oncolytic virotherapy achieves clinical proof-of-concept.
    Mol Ther; 2006 Feb; 13(2):237-8. PubMed ID: 16376156
    [No Abstract]   [Full Text] [Related]  

  • 7. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.
    Fujiwara T; Shirakawa Y; Kagawa S
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):525-32. PubMed ID: 21504319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
    Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
    Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Armed interference: oncolytic viruses engineered to carry antitumor shRNAs.
    Kirn D
    Mol Ther; 2007 Feb; 15(2):227-8. PubMed ID: 17235298
    [No Abstract]   [Full Text] [Related]  

  • 10. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancer.
    Fujiwara T; Kagawa S; Tazawa H
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1809-16. PubMed ID: 21740362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer.
    Machitani M; Sakurai F; Wakabayashi K; Tachibana M; Fujiwara T; Mizuguchi H
    Mol Cancer Ther; 2017 Jan; 16(1):251-259. PubMed ID: 27760834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer gene therapy with oncolytic adenoviruses.
    Guse K; Hemminki A
    J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chapter four--Design of improved oncolytic adenoviruses.
    Alemany R
    Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
    Torres-Domínguez LE; de Matos AL; Rahman MM; McFadden G
    Methods Mol Biol; 2021; 2225():63-75. PubMed ID: 33108657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in oncolytic adenovirus therapies for cancer.
    Rosewell Shaw A; Suzuki M
    Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
    Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
    Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic-adenovirus-expressed RNA interference for cancer therapy.
    Pei DS; Di JH; Chen FF; Zheng JN
    Expert Opin Biol Ther; 2010 Sep; 10(9):1331-41. PubMed ID: 20684738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.
    Aoyama K; Kuroda S; Morihiro T; Kanaya N; Kubota T; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Sci Rep; 2017 Oct; 7(1):14177. PubMed ID: 29074882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.